title: The Utility of Serum CA9 for Prognostication in Prostate Cancer.
abstract: Carbonic anhydrase IX (CA9) catalyses the interconversion of carbon dioxide to carbonic acid and bicarbonate and is considered a putative biomarker of tumour hypoxia. We set out to evaluate the prognostic significance of CA9 in prostate cancer.
  
  
  
  Plasma samples were assessed from 68 men with high-risk localised prostate cancer treated with radical prostatectomy (RP) or radiotherapy (RT), and 20 men with castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy between 2010 and 2012 at the Princess Margaret Cancer Centre, Canada.
  
  
  
  Of the 68 patients with high-risk localised prostate cancer, 57 underwent RP and 11 underwent RT. Baseline CA9 was not associated with recurrence or prostate-specific antigen in either group (p=0.98 and 0.20, respectively). CA9 levels before chemotherapy correlated with overall survival (r=-0.37; two-sided p=0.11).
  
  
  
  Baseline CA9 in men with CRPC may portend a more aggressive prostate cancer phenotype with poorer survival.
authors.affiliation: Princess Margaret Cancer Centre, Toronto, ON, Canada alan.smith@uhn.ca.
authors.forename: Alan D
authors.initials: AD
authors.lastname: Smith
authors.affiliation: Department of Biochemistry, University of Toronto, Toronto, ON, Canada.
authors.forename: Mathew
authors.initials: M
authors.lastname: Truong
authors.affiliation: Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: Rob
authors.initials: R
authors.lastname: Bristow
authors.affiliation: Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: Paul
authors.initials: P
authors.lastname: Yip
authors.affiliation: Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: Michael F
authors.initials: MF
authors.lastname: Milosevic
authors.affiliation: Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: Anthony M
authors.initials: AM
authors.lastname: Joshua
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D000071231:Carbonic Anhydrase IX / Q000097:blood*; D000077143:Docetaxel; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis*; D010641:Phenotype; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX
keywords: CA9; CAIX; Prostate cancer; biomarker